The global Cancer Biological Therapy Market is entering a transformative decade, fueled by breakthroughs in precision ...

The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...

A promising new treatment for Lyme disease, a condition transmitted through tick bites, is in development and aims to offer ...

Researchers evaluated whether interferon-α nasal spray reduces the incidence of COVID-19 or other respiratory viral infections among adults with cancer.

Hospitalizations due to RSV cases in infants are reduced by up to 43% following the introduction of new maternal vaccines.

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

Leqembi ® Iqlik™, a subcutaneous (SC) formulation of lecanemab, is now available as a maintenance dosing regimen for the treatment of Alzheimer disease in patients with mild cognitive impairment or ...

Sanofi and Galderma are competitors in the pharmaceutical space. Galderma’s Nemluvio is a monoclonal antibody approved by the FDA to treat adults with PN, and to treat moderate-to-severe eczema in ...

Jade Biosciences (NASDAQ:JBIO) shares surged 20% on Tuesday after the clinical-stage biotech company unveiled JADE201, a new ...

Corbus Fireside Chat October 9, 2025, 10:00AM ET Hosted by Biren Amin, Managing Director Pipe Sandler - Healthcare Equity Research ...

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell ...

Jade Biosciences (JBIO) unveiled JADE201, its investigational half-life extended, afucosylated monoclonal antibody targeting the B-cell activating ...